INTRODUCTION
============

Ischemic stroke terms a condition caused by the occlusion of a blood vessel supplying the brain ([@b6-jer-14-6-1096]) and represents more than 80% of all stroke cases ([@b4-jer-14-6-1096]; [@b9-jer-14-6-1096]). Recent evidence indicates that inflammation plays an important role in ischemic stroke ([@b17-jer-14-6-1096]). Chronic inflammatory response is associated with stroke and neurodegenerative diseases ([@b10-jer-14-6-1096]; [@b15-jer-14-6-1096]). Moreover, after cerebral ischemia, the death of ischemic neurons and the release of necrotic cell debris trigger a robust inflammatory reaction ([@b14-jer-14-6-1096]; [@b24-jer-14-6-1096]; [@b26-jer-14-6-1096]). Many therapeutic trials for inflammation-associated brain injuries have been applied ([@b8-jer-14-6-1096]; [@b12-jer-14-6-1096]; [@b23-jer-14-6-1096]).

Nuclear factor-kappaB (*NFKB*) is a major transcription regulator of immune response, apoptosis, and cell-growth control genes ([@b13-jer-14-6-1096]). It plays a central role in modulation of inflammation ([@b19-jer-14-6-1096]). The *NFKB* names a variety of transcription factors that are homo- or hetero-dimers of p50, p52, p65, RelB, and c-Rel ([@b21-jer-14-6-1096]; [@b22-jer-14-6-1096]). Of those subunits, the p50, encoded by *NFKB1* gene, is known to have both pro- and anti-inflammatory properties. The p50/p65 heterodimer stimulates transcription of pro-inflammatory cytokines, whereas the p50/p50 homodimer induces transcription of anti-inflammatory cytokine ([@b5-jer-14-6-1096]; [@b11-jer-14-6-1096]; [@b21-jer-14-6-1096]; [@b22-jer-14-6-1096]). Thus, the expression of *NFKB1* gene may be related to balancing the inflammatory response ([@b21-jer-14-6-1096]).

Considering the known relevance of inflammation in ischemic stroke, a possible role of *NFKB1* gene polymorphisms on susceptibility to ischemic stroke cannot be ruled out. We analyzed single nucleotide polymorphism (SNP) in the promoter of *NFKB1* gene and investigated the genetic association between susceptibility of ischemic stroke and *NFKB1* gene in Korean population.

MATERIALS AND METHODS
=====================

Subjects
--------

One hundred twenty-one Korean adult patients with ischemic stroke (65.7±12.1 years in age, mean±standard deviation) and 291 Korean healthy controls (63.0±9.3 years) were enrolled for this study. The patient group was comprised of 68 males and 53 females. Each patient was diagnosed using the cranial computed tomography, magnetic resonance imaging (MRI), or angiography. The patients were classified by well-trained two physicians into clinical phenotypes according to the results of the National Institutes of Health Stroke Survey (NIHSS) and the Modified Barthel Index (MBI), respectively. The neurological deficit on admission was measured using the NIHSS. The outcome at hospital discharge was assessed using the MBI. Patients with trauma, vascular malformations, brain tumors, and congenital brain disorders were excluded. The control group was comprised of 152 men and 139 women. Healthy control subjects were selected among participants examined in a general health check-up program. Participants with transient ischemic attack, ischemic heart diseases, and other atherosclerotic diseases were excluded. Age and gender of the control group was matched with those of the patient group. A summary of demographic findings of ischemic stroke patients and control subjects were provided in [Table 1](#t1-jer-14-6-1096){ref-type="table"}. Written informed consent was obtained from each patient or the legal guardian. The protocol for this study was approved by the ethics review committee of the Medical Research Institute, School of Medicine, Kyung Hee University (Seoul, Korea).

SNP selection and genotyping
----------------------------

We searched SNPs of *NFKB1* gene in the coding and promoter regions. Relevant information was obtained from the National Center for Biotechnology Information SNP database (<http://www.ncbi.nlm.nih.gov/SNP>; dbSNP BUILD 131). There were 16 SNPs with a heterozygosity \>0.1 in the coding and promoter regions of *NFKB1*. Of those SNPs, all of 6 SNPs in the coding region and 9 of 10 SNPs in the promoter region were excluded because of monomorphic genotype. Consequently, rs11940017 (−1727, C/T) in the promoter region was selected.

Peripheral blood samples were collected from each subject and then stored in a −20°C refrigerator. Genomic DNA was extracted from the blood samples using a QIAamp DNA mini kit (QIAGEN, Valencia, CA, USA). SNP genotyping was conducted by direct sequencing (MACROGEN, Seoul, Korea). Polymerase chain reactions (PCRs) were performed with specific primer for rs11940017 ([Table 2](#t2-jer-14-6-1096){ref-type="table"}). The PCR products were sequenced using an ABI PRISM 3730XL DNA Analyzer (PE Applied Biosystems Inc., Foster City, CA, USA). Sequence data were analyzed using SeqManII software (DNASTAR Inc., Madison, WI, USA).

Statistical analysis
--------------------

The SNPStats (Biostatistics and Bioinformatics Unit, Barcelona, Spain) was used to analyze genetic data. Hardy-Weinberg equilibrium (HWE) was assessed. The effects of SNP genotypes were analyzed using 4 models; codominant (codominant 1: T/T \[reference\] vs. T/C; codominant 2: T/T vs. C/C), dominant (T/T \[reference\] vs. T/C+C/C), recessive (T/T+T/C \[reference\] vs. C/C), and log- additive (T/T vs. T/C vs. C/C) models ([@b27-jer-14-6-1096]; [@b28-jer-14-6-1096]). Logistic regression analyses were used to calculate the odds ratios (ORs), 95% confidence intervals (CIs), and *P*-values with controlling age and gender as covariables. Allele frequencies were compared by Pearson chi-square test. Statistical analyses were performed using SPSS ver. 17.0 (SPSS Inc., Chicago, IL, USA). The significance level for statistical test was set at *P*-value of \<0.05.

RESULTS
=======

Genotype distribution of rs11940017 SNP (−1727, C/T) of *NFKB1* gene in the control group was consistent with the HWE (*P*\>0.05; data not shown). The genotyping data revealed that rs11940017 SNP (−1727, C/T) was associated with the susceptibility of ischemic stroke ([Table 3](#t3-jer-14-6-1096){ref-type="table"}). The frequencies of T/T, T/C, and C/C genotypes were 86.2%, 12.4%, and 1.4%, respectively in the control group, and 95.0%, 5.0%, and 0% in the ischemic stroke group, respectively. The T/C genotype was associated with a decreased risk of ischemic stroke, compared to the T/T genotype (codominant model; OR, 0.38; 95% CI, 0.15--0.92; *P*=0.032). In the analysis using the dominant model, the genotype containing C allele (T/C and C/C) was associated with a decreased risk of ischemic stroke, compared to the T/T genotype (OR, 0.33; 95% CI, 0.14--0.81; *P*=0.0068). The frequencies of T and C alleles were 92.4% and 7.6%, respectively in the control group, and 97.5% and 2.5%, respectively in the ischemic stroke group (OR, 0.31; 95% CI, 0.13--0.74; *P*=0.008). These data suggest that the promoter SNP (rs11940017, −1727, C/T) of *NFKB1* gene was associated with susceptibility of ischemic stroke.

DISCUSSION
==========

The relation between peripheral immune cells and the brain has been suggested ([@b20-jer-14-6-1096]). In this study, we observed that the *NFKB1* promoter polymorphism, rs11940017 (−1727, C/T), was associated with ischemic stroke. We particularly found that the C allele of rs11940017 might contribute to a decreased risk of ischemic stroke in Korean population.

The *NFKB1* gene encodes a 105 kD non-DNA-binding protein (p105) of nuclear factor-kappa B (NF-κB), which can undergo cotranslational processing to produce a 50-kD DNA-binding protein (p50) ([@b13-jer-14-6-1096]). NF-κB names a number of different transcription factors that are homo- or hetero-dimers of p50, p52, p65, RelB and c-Rel ([@b21-jer-14-6-1096]; [@b22-jer-14-6-1096]). The major form of NF-κB is a heterodimer of the p50 and p65 subunits ([@b7-jer-14-6-1096]). The p50 subunit, encoded by *NFKB1* gene, has both pro- and anti-inflammatory properties: As part of the p50/p65 heterodimer, the p50 controls transcription of pro-inflammatory cytokines such as tissue necrosis factor and interleukin-1β ([@b22-jer-14-6-1096]). In the p50/p50 homodimer, it has anti-inflammatory properties by repressing transcription of pro-inflammatory cytokines and by stimulating transcription of anti-inflammatory cytokine ([@b5-jer-14-6-1096]; [@b11-jer-14-6-1096]; [@b21-jer-14-6-1096]). Thus, the relative abundance of p50/p65 heterodimers and p50 homodimers may determine the magnitude of inflammation by balancing the pro-inflammatory and anti-inflammatory responses ([@b21-jer-14-6-1096]). If an altered *NFKB1* transcription would lead to a decreased p50 synthesis, fewer p50 homodimers may be formed and a stronger activation of transcription of pro-inflammatory genes can be induced ([@b3-jer-14-6-1096]). Given this role in inflammatory processes, polymorphisms in the promoter of *NFKB1* may modulate the susceptibility to ischemic stroke because inflammation is a risk factor for ischemic stroke.

Some clinical studies investigated a relation between a functional promoter polymorphism of *NFKB1* gene and immune-mediated diseases including ulcerative colitis ([@b3-jer-14-6-1096]; [@b13-jer-14-6-1096]), acute respiratory distress syndrome ([@b1-jer-14-6-1096]; [@b2-jer-14-6-1096]), cervical cancer, dilated cardiomyopathy ([@b29-jer-14-6-1096]), and coronary heart disease ([@b25-jer-14-6-1096]). However, the genetic association between *NFKB1* polymorphisms and ischemic stroke has not been published in the literature, even though the NF-κB pathway is suggested as one of mechanisms of ischemic stroke ([@b16-jer-14-6-1096]; [@b18-jer-14-6-1096]). Thus, we searched SNPs in the promoter and coding regions of *NFKB1* gene and selected a promoter polymorphism, rs11940017. In our data, the C allele was the minor allele of rs11940017 and was related to a lower risk of ischemic stroke (OR, 0.31; 95% CI, 0.13--0.74). The genotype containing C allele was further decreased in patients with ischemic stroke. We presumed that the relative frequency of the T and C alleles of rs11940017 might be able to alter the activity of *NFKB1* transcription. We expect, in the further study, to simultaneously investigate the genotype frequencies and the NF-κB activity between ischemic stroke patients and control subjects.

In conclusion, we found statistically significant association between rs11940017 SNP of *NFKB1* gene and the susceptibility to ischemic stroke in Korean population. Here in this study, we report a relation between *NFKB1* gene and ischemic stroke.
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###### 

Demographic findings of the study subjects

  Variable        Ischemic stroke (n=12)   Control (n=291)
  --------------- ------------------------ -----------------
  Age (yr)        65.7±12.1                63.0±9.3
                                           
  Gender                                   
   Male           68 (56.2)                152 (52.2)
   Female         53 (43.8)                139 (47.8)
                                           
  NIHSS (score)                            
   \<6            56                       \-
   ≥6             57                       \-
                                           
  MBI (score)                              
   \<60           71                       \-
   ≥60            25                       \-

Values are presented as mean±standard deviation or number (%) unless otherwise indicated.

NIHSS, National Institutes of Health Stroke Survey; MBI, Modified Barthel Index.

###### 

Sequence of primer used for the SNP

  SNP                                                Sequence (5′-3′)         Product size (bp)   Annealing temperature (°C)
  ------------------------- ------------------------ ------------------------ ------------------- ----------------------------
  rs11940017 (−1727, C/T)   Sense                    CATCTCCTCTCTCTGCCAAGTT   391                 59
  Antisense                 GAACCTGGGGGGAGGGGTTACT   \-                       \-                  

SNP, single nucleotide polymorphism.

###### 

Genotype and allele frequencies of *NFKB1* polymorphism in control subjects and ischemic stroke patients

  SNP                                Genotype & allele   Control      Ischemic stroke   Model          OR (95% CI)         *P*-value
  ---------------------------------- ------------------- ------------ ----------------- -------------- ------------------- ------------------------------------------------------
  rs11940017 promoter (−1727, C/T)   Genotype                                                                              
                                     T/T                 251 (86.2)   115 (95.0)        Codominant 1   0.38 (0.15--0.92)   0.032[\*](#tfn7-jer-14-6-1096){ref-type="table-fn"}
                                     T/C                 36 (12.4)    6 (5.0)           Codominant 2   0.00 (0.00--NA)     NA
                                     C/C                 4 (1.4)      0 (0)             Dominant       0.33 (0.14--0.81)   0.0068[\*](#tfn7-jer-14-6-1096){ref-type="table-fn"}
                                                                                        Recessive      0.00 (0.00--NA)     NA
                                                                                        Log-additive   0.38 (0.16--0.94)   0.021[\*](#tfn7-jer-14-6-1096){ref-type="table-fn"}
                                                                                                       0.34 (0.15--0.80)   0.0043[\*](#tfn7-jer-14-6-1096){ref-type="table-fn"}
                                     Allele                                                                                
                                     T                   538 (92.4)   236 (97.5)                       Reference           
                                     C                   44 (7.6)     6 (2.5)                          0.31 (0.13--0.74)   0.008[\*](#tfn7-jer-14-6-1096){ref-type="table-fn"}

*NFKB1*, nuclear factor of kappa light polypeptide gene enhancer in B-cells 1; SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval; NA, not applicable.

*P*-values were from logistic regression analyses with codominant, dominant, recessive and log-additive models.

Codominant 1, T/T genotype (reference) vs. T/C genotype; Codominant 2, T/T genotype (reference) vs. C/C genotype; Dominant, T/T genotype (reference) vs. T/C+C/C genotypes; Recessive, T/T+T/C genotypes (reference) vs. C/C genotype; Log-additive, T/T genotype vs. T/C genotype vs. C/C genotype.

*P*\<0.05, statistically significant.
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